Authors: Éric Bergeron, Cheng-Feng Chiang, Michael K. Lo, Elif Karaaslan, Syed Moinuddin Satter Mohammed Ziaur Rahman, Mohammad Enayet Hossain, Wasik Rahman Aquib, Dewan Imtiaz Rahman, Subyeta Binte Sarwar, Joel M. Montgomery, John D. Klena, Christina F. Spiropoulou
Year: 2024
Journal: Emerging Microbes & Infections
DOI: 10.1080/22221751.2024.2398640
Summary#
Researchers developed and validated a split NanoLuc luciferase NiV glycoprotein (G) biosensor for detecting antibodies in clinical and animal samples. The assay was tested using the WHO’s first international standard for anti-NiV antibodies and more than 700 serum samples from Bangladesh, showing sensitivity and specificity comparable to anti-NiV IgG ELISA performance.
Key Findings#
- The developed assay can detect antibodies in clinical and animal samples
- Anti-NiV antibodies persisted for at least 8 years according to both ⍺NiV-G mix-and-read and NiV neutralization assays
- The sensitivity (98.6%) and specificity (100%) of the anti-NiV-G biosensor were comparable to anti-NiV IgG ELISA performance
Methodology#
- Study Type: Experimental
- Sample Size: More than 700 serum samples
- Geographic Focus: Bangladesh
Topics#
Nipah virus, serology, disease surveillance, antibodies, paramyxoviridae
Relevance#
The anti-NiV-G biosensor could support the expansion of NiV surveillance and retrospective outbreak investigations.